SCHEMBL10122969

SCHEMBL10122969

CN1CCN(c2cc(Nc3cc(C(C)(C)C)[nH]n3)nc(/C=C/c3ccccc3)n2)CC1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 13/20 0.77
RET P07949 5/20 0.77
NTRK1 P04629 5/20 0.77
AURKB Q96GD4 4/20 0.77
KDR P35968 4/20 0.77
FLT3 P36888 4/20 0.77
PLK4 O00444 2/20 0.77
ABL1 P00519 2/20 0.77
LCK P06239 2/20 0.77
CSF1R P07333 2/20 0.77
KIT P10721 2/20 0.77
FGFR1 P11362 2/20 0.77
SRC P12931 2/20 0.77
PDGFRA P16234 2/20 0.77
TYK2 P29597 2/20 0.77
PTK2 Q05397 2/20 0.77
MAP4K5 Q9Y4K4 2/20 0.77
FGFR3 P22607 2/20 0.77
FLT1 P17948 2/20 0.77
CHEK1 O14757 1/20 0.77

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Enmd-2076 SCHEMBL10122872 0.87 AURKA (1.00) AURKARETNTRK1AURKBKDR
Enmd-2076 SCHEMBL10122873 0.87 AURKA (1.00) AURKARETNTRK1AURKBKDR
Enmd-2076 SCHEMBL29355178 0.87 AURKA (1.00) AURKARETNTRK1AURKBKDR
Enmd-2076 SCHEMBL15668060 0.87 AURKA (1.00) AURKARETNTRK1AURKBKDR
SCHEMBL10122970 0.86 AURKA (0.80) AURKARETNTRK1AURKBKDR
SCHEMBL10312204 0.84 RET (0.55) AURKARETNTRK1AURKBKDR
SCHEMBL10122967 0.84 AURKA (0.76) AURKARETNTRK1AURKBKDR
SCHEMBL10122878 0.82 AURKA (0.73) AURKARETNTRK1AURKBKDR
SCHEMBL10122902 0.82 AURKA (0.89) AURKARETNTRK1AURKBKDR
SCHEMBL10122972 0.81 AURKA (0.72) AURKARETNTRK1AURKBKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8114870-B2 Method of treating disease states using substituted pyrazole compounds MIIKANA THERAPEUTICS, INC. (US) 2012-02-14 US disclosed
US-8114870-B2 Method of treating disease states using substituted pyrazole compounds MIIKANA THERAPEUTICS, INC. (US) 2012-02-14 US disclosed
US-20090264422-A1 METHOD OF TREATING DISEASE STATES USING SUBSTITUTED PYRAZOLE COMPOUNDS MIIKANA THERAPEUTICS, INC. 2009-10-22 US disclosed
US-20090264422-A1 METHOD OF TREATING DISEASE STATES USING SUBSTITUTED PYRAZOLE COMPOUNDS MIIKANA THERAPEUTICS, INC. 2009-10-22 US disclosed
US-7563787-B2 Substituted pyrazole compounds MIIKANA THERAPEUTICS, INC. (US) 2009-07-21 US disclosed
US-7563787-B2 Substituted pyrazole compounds MIIKANA THERAPEUTICS, INC. (US) 2009-07-21 US disclosed
US-20070142368-A1 Substituted pyrazole compounds MIIKANA THERAPEUTICS, INC. 2007-06-21 US disclosed
US-20070142368-A1 Substituted pyrazole compounds MIIKANA THERAPEUTICS, INC. 2007-06-21 US disclosed
WO-2007041358-A2 SUBSTITUTED PYRAZOLE COMPOUNDS MIIKANA THERAPEUTICS, INC. (US) 2007-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070142368-A1 Substituted pyrazole compounds AURKC, AURKA, AURKB AURKA 2/4885RET 1222/4885NTRK1 2241/4885
US-20090264422-A1 METHOD OF TREATING DISEASE STATES USING SUBSTITUTED PYRAZOLE COMPOUNDS AURKC, AURKA, AURKB AURKA 2/4885RET 1676/4885NTRK1 2217/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.